Comparison of Four Front-Line Doublets in Asian Patients With Metastatic Gastric Cancer
In a Phase II trial, four front-line chemotherapy doublets were compared for treatment of patients with metastatic gastric cancer. While... Read More
Our Impact
Gastric Cancer Foundation improves the lives of people affected by gastric (stomach) cancer by supporting patient education initiatives and innovative research studies to improve treatments and ultimately, find a cure.
Support Research for a Cure
Every contribution to Gastric Cancer Foundation makes a difference. Honor a loved one, make a tribute to someone’s memory, honor a happy occasion by making a meaningful donation.
-
Second primary cancers and survival in patients with gastric cancer: association with prediagnosis lifestyles
Heavy alcohol consumption and an unhealthy diet prior to a diagnosis of gastric cancer can affect treatment outcomes, a new... Read More
Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer
A new study suggests that adding docetaxel to fluoropyrimidine post surgery is effective in stage 3 gastric cancer.
Nutrition for Patients With Mucositis
Dr. Jann Arends discusses the importance of considering nutritional treatment for #cancer patients with mucositis, painful inflammation and ulceration of... Read More
Perioperative Fluorouracil + Leucovorin, Oxaliplatin, and Docetaxel vs Fluorouracil or Capecitabine + Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or GE Junction Adenocarcinoma
A phase II/III trial investigated a chemotherapy triplet, FLOT (docetaxel, oxaliplatin, 5-FU/LV), as perioperative therapy in resectable gastroesophageal cancers compared... Read More
Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers
A large randomized trial concluded that Vitamin D supplementation does not improve relapse-free survival in patients with cancers of the... Read More
Cancer prevention drug also disables H. pylori bacterium
Researchers have discovered that a medicine currently being tested as a chemoprevention agent for multiple types of cancer also disables... Read More
Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
“We continue to be very encouraged by the tolerability and antitumor activity of margetuximab with an anti-PD-1 mAb, an investigational,... Read More
Taiho Oncology and Servier Present Data on LONSURF (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)
A new study evaluating LONSURF in patients with previously treated metastatic gastric cancer is consistent with the overall study results... Read More
Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
“Gastric cancer with FGFR2b overexpression or FGFR2 gene amplification is associated with a poor prognosis for patients with advanced disease,”... Read More
Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study
Presented at last week’s ASCO Gastrointestinal Cancers Symposium, noteworthy studies incuded new approaches to treating and managing gastric cancer including... Read More
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Researchers evaluated the addition of the AKT inhibitor ipatasertib to mFOLFOX6 for patients with gastric cancer.
Citrus fruit intake and gastric cancer: The stomach cancerpooling (StoP) project consortium
A new study in International Journal of Cancer evaluated the link between eating citrus fruit and gastric cancer risk, finding... Read More
Biotech Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
An early stage drug tested in a new study shows promising results for gastric cancer patients.
Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials
A new study in Oncology Advance looks at the association between quality of life, disease characteristics, and treatment outcomes in... Read More
A Conceptual Overview of Targeted Therapy in GI Cancers
Watch this PracticeUpdate video for an overview of gastric cancer treatments (register for free to view).-
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: Results from the randomized prospective phase III FFCD-0307 trial
New research shared in MD Linx looks at prognostic factors in patients with advanced gastric cancer treated with second-line chemotherapy. 
Clinicopathological significance of RCAN2 production in gastric carcinoma
Researchers examined calcineurin 2 (RCAN2) regulators and expression patters, finding RCAN2 is correlated with tumor progression and an independent prognostic... Read More
Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends
A review of evolving trends in third line treatment of advanced gastric cancer shows sequential treatment approaches benefit a growing... Read More-
ENA NEWS: Patients with cancers of the gullet, stomach and bowel respond well to new anti-HER2 drug
New research published in European Cancer finds gastric cancer patients respond well to a new anti-HER2 drug, which binds to... Read More
Monthly Newsletter
We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.